Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.

Lee JM, Brady MF, Miller A, Moore RG, MacKay H, McNally L, Lea J, Street D, Lheureux S, McDonald ME, Duska LR, Cantuaria G, Kavecansky J, Leath CA 3rd, Powell M, Cadungog MG, Rose PG, Kim YM, Huang HQ, Provencher M, Wenzel LB, Bookman MA, Kohn EC, Secord AA

Open source

DOI: 10.1200/jco.24.00683
Published: 2024 Dec 20
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.24.00683,
  title = {Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.},
  author = {Lee JM and Brady MF and Miller A and Moore RG and MacKay H and McNally L and Lea J and Street D and Lheureux S and McDonald ME and Duska LR and Cantuaria G and Kavecansky J and Leath CA 3rd and Powell M and Cadungog MG and Rose PG and Kim YM and Huang HQ and Provencher M and Wenzel LB and Bookman MA and Kohn EC and Secord AA},
  year = {2024},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco.24.00683},
  url = {https://doi.org/10.1200/jco.24.00683}
}

RIS

TY  - JOUR
TI  - Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
AU  - Lee JM
AU  - Brady MF
AU  - Miller A
AU  - Moore RG
AU  - MacKay H
AU  - McNally L
AU  - Lea J
AU  - Street D
AU  - Lheureux S
AU  - McDonald ME
AU  - Duska LR
AU  - Cantuaria G
AU  - Kavecansky J
AU  - Leath CA 3rd
AU  - Powell M
AU  - Cadungog MG
AU  - Rose PG
AU  - Kim YM
AU  - Huang HQ
AU  - Provencher M
AU  - Wenzel LB
AU  - Bookman MA
AU  - Kohn EC
AU  - Secord AA
PY  - 2024
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco.24.00683
UR  - https://doi.org/10.1200/jco.24.00683
ER  -

APA

JM, L., MF, B., A, M., RG, M., H, M., L, M., J, L., D, S., S, L., ME, M., LR, D., G, C., J, K., 3rd, L. C., M, P., MG, C., PG, R., YM, K., HQ, H., M, P., LB, W., MA, B., EC, K., & AA, S. (2024). Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco.24.00683

Source records

pubmed · retrieved 2026-09-27T10:42:34.980Z